ProfileGDS5678 / 1434630_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 80% 81% 80% 81% 82% 82% 81% 79% 85% 83% 80% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4736979
GSM967853U87-EV human glioblastoma xenograft - Control 25.6556280
GSM967854U87-EV human glioblastoma xenograft - Control 35.7668181
GSM967855U87-EV human glioblastoma xenograft - Control 45.7971280
GSM967856U87-EV human glioblastoma xenograft - Control 55.8112281
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7923382
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7900482
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7419181
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4889579
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3971685
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1337283
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7515280
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9766682
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9586382